researcher59
5 minutes ago
JAZZ posts solid Q2 results .....
briefing -
Jazz Pharma beats by $0.53, beats on revs; guides FY24 EPS above consensus, revs in-line (110.25 -2.02) :
Reports Q2 (Jun) earnings of $5.30 per share, excluding non-recurring items, $0.53 better than the FactSet Cons